Erwinia asparaginase, methotrexate-these are 2 drugs that have been used to treat childhood cancer for years. Currently, Erwinia asparaginase is not available at all, and methotrexate is in short supply. Most drugs used to treat cancer in children are imore than 20 years old. Many new therapies are not licensed for use in children. Other chemotherapy agents that show promise in pediatric clinical trials may never be produced after the study data are reported due to the limited demand for the drug. For example, it may be difficult to find a company to manufacture a drug that is used in only a few hundred children each year. The number of pediatric patients affected by the disease or condition in the United States for which the drug is intended must meet the statutory prevalence limit of 200 000, or if the number exceeds 200 000 the costs of drug development cannot be reasonably recovered by drug sales in the United States.
The Food and Drug Administration (FDA) has long recognized pediatric patients as "therapeutic orphans" due to the lack of adequate pediatric dosing information among drugs that are on the market. In the pediatric population, growth and developmental changes can influence the way drugs are absorbed, distributed, metabolized, and excreted, which are vastly different from that of the adult.
Very recently, clofarabine was approved by the FDA for use in the treatment of pediatric patients 1 to 21 years old who have relapsed or refractory acute lymphoblastic leukemia that developed after at least 2 regimens of treatment. This was the first time in years since a new anticancer drug received approval for pediatric use before approval for adult use. This occurred in part because clofarabine was granted fast-track status because of its potential to treat a serious, life-threatening condition and address an unmet medical need. In addition, the Best Pharmaceuticals O 200'i5 bv As.ci(tiO17 (f o lPedi(ltric 0ocology Nurses for Children Act offers extended market exclusivity to drug developers as an incentive to increase therapeutic research in children. This is an economic incentive for drug companies to pursue clinical drug development oir children in a small subset of the population. Unfortunately, it still costs more for manufacturers to develop drugs specifically for use in children than the drug will potentially earn. We still have a long way to go, but there are some hopeful approaches.
The National Cancer Institute has recently created a program to screen promising drugs in the lab each year against common pediatric tumors, and eventually, due to advances in molecular biology, it may be possible to design cancer therapy based on the biology of the tumor regardless of whether the patient is an adult or a child.
In the meantime, pediatric oncology nurses must remain aware of drug development, advances in drug therapies, and access to experimental and investigational trials for children with cancer. Educating patients and families who enroll in clinical trials is a crucial part of our practice. Many families are willing to do their part, and it is our role to support them. We also must remain aware of what is going on at the governmental level in terms of orphan drug development and politically advocate for our patients. Nanicy F. Mille, PhD, RN, CPNP, FAAN Edritor In-ChU' In addition to members of the Editorial Board, I would like to acknowledge the following individuals for their expert review of manuscripts submitted to the Journal in 2005:
